ACTRN12613000302752
Withdrawn
Phase 1
A phase I/Ib study to determine the safety and tolerability of Dz13 DNAzyme targeting c-Jun, administered to subjects with in-transit or satellite melanoma metastases via single intra tumoural injections of 100 mcg twice weekly
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- in-transit or satellite melanoma
- Sponsor
- The University of New South Wales
- Enrollment
- 38
- Status
- Withdrawn
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosed dermal in\-transit or satellite metastatic melanoma with at least 3 measurable lesions at minimum distance of 5 cm from each other
- •ECOG performance status 0\-1
- •Acceptable haematologic, coagulation, renal and hepatic function
Exclusion Criteria
- •Metastatic/in\-transit or satellite lesions located on face, head and neck
- •Women of child bearing age
- •Prior or co\-existing malignancy
- •Radiotherapy to \>30% bone marrow in previous 3 months
- •Clinically significant non\-malignant disease
- •Current immunosuppression
- •History of immune\-mediated throbocytopenia or other platelet disease
- •Enrolment in another clinical study involving any other investigational agent
Outcomes
Primary Outcomes
Not specified
Similar Trials
Withdrawn
Phase 1
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 3.MalariaInfection - Other infectious diseasesACTRN12613000533796CPR Pharma Services24
Completed
Phase 1
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 1.ACTRN12613000522718CPR Pharma Services73
Completed
Phase 1
A Phase I/Ib Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of DSM265 in Healthy Subjects and to Assess the Antimalarial Activity of DSM265 in Healthy Subjects with an Induced Blood Stage Plasmodium falciparum Infection.PART 2.MalariaInfection - Other infectious diseasesACTRN12613000527763CPR Pharma Services10
Completed
Phase 1
A phase I study of the Dz13 drug targeting the c-Jun gene in subjects with skin cance (nodular Basal Cell Carcinoma).ACTRN12610000162011niversity of New South Wales9
Withdrawn
Phase 2
A Phase I/II study to determine the safety and efficacy of a combination of anti-CD3 & anti-CD7 ricin A immunotoxins for treating steroid-resistant acute graft-versus-host disease.Immuunsysteemaandoeningen: acute omgekeerde afstotingsziekteacute graft-versus-host diseaseGVHDNL-OMON31737Henogen S.A.12